Greg Weaver joined atai as consulting CFO in July 2020 and assumed the position permanently in September 2020. Greg has over 25 years of Chief Financial Officer and board director experience in the biotech industry.
Greg’s career has focused on start-up through clinical development and commercial stage. He has guided over $1.1 billion in financing transactions during his career, participated in several public and private financings, providing financial guidance, strategic leadership and shareholder value. Prior to joining atai, Mr. Weaver was CFO at several successful companies, including SIRNA Therapeutics, ILEX Oncology, Oryzon, Prometic, and Eloxx Pharmaceuticals.
Mr. Weaver holds an undergraduate degree in accounting from Trinity University (San Antonio, TX), and an MBA from Boston College.